Dr. Sonali Smith discusses the newest developments in the treatment of CML.
European Commission Grants Marketing Authorization to Obe-Cel in R/R B-ALL
Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy
Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML
A PDUFA date for decitabine/cedazuridine and venetoclax in newly diagnosed AML has been set for February 25, 2026.
Immunotherapy Approaches in AML
Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.
FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML
The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.
Bexobrutideg Achieves High Objective Response Rate in Heavily Pretreated R/R CLL
Bexobrutideg, a novel BTK degrader, demonstrated preliminary clinical activity and a consistent safety profile in patients with relapsed/refractory chronic lymphocytic leukemia.
